# GFBiochemicals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gfbiochemicals

- Industry: Chemicals
- Headquarters: Geleen, Netherlands
- Website: www.gfbiochemicals.com
- Total disclosed funding: $16M
- Latest round: Series A (May 5, 2022)
- Investors on record: 2

## About

GFBiochemicals Ltd. is an innovative company specializing in the production of bio-based chemical ingredients, particularly using levulinate technologies to replace traditional fossil fuel-derived chemicals in various industries.Founded in 2008 by Mathieu Flamini and Pasquale Granata, GFBiochemicals Ltd. is headquartered in Geleen, Netherlands. The company has undergone a Series A funding round on May 5, 2022, raising EUR 15.000 mn led by Sofinnova Partners with participation from Sparta Capital Management. This funding round marked the company's first significant investment since its inception and reflects a strategic pivot towards enhancing manufacturing capabilities and developing new product lines.GFBioChemicals specializes in the production of bio-based ingredients, focusing on levulinate technologies. Core products include Ethyl Levulinate, Butyl Levulinate, Levulinate Propanediol Ketal, and proprietary formulations like SOLVE100, MOVE200, CLEAN300, and NEW320. These products serve various sectors including plastics, cosmetics, and detergents, providing sustainable alternatives to traditional chemicals.GFBioChemicals generates revenue through direct sales of its bio-based products to manufacturers emphasizing sustainability. Operating primarily on a B2B model, the company structures pricing according to order volume and specific agreements. Notable products like SOLVE100 and CLEAN300 are provided through long-term contracts, establishing firm relationships with clients across retail and wholesale sectors.Following the recent EUR 15.000 mn funding round in May 2022, GFBiochemicals plans to build strategic partnerships, invest in research and development, and support its manufacturing facility. The company aims to extend its portfolio of patents and hire new talent for sales and marketing, particularly in the US and Europe, to facilitate market expansion and the development of upcoming bio-based products.

## Funding rounds

- Series A, May 5, 2022, $16M — Sofinnova Partners, Sparta Capital Management

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Sparta Capital Management — Series A